

ASX RELEASE**Trajan Group Investment in direct-to-consumer health measurement business.**

November 4th 2021 – Global analytical science and device company Trajan Group Holdings Limited (**ASX: TRJ**) (**Trajan or the Company**) has entered into a binding agreement to secure equity and a board position in Humankind Ventures (Trading as FORTH, Chepstow, UK). Forth provides a range of at-home sampling and testing services based on microsampling approaches. The investment supports Trajan's strategy towards health technology that interfaces directly with the consumer.

Kayte Parlevliet, Trajan's General Manager - Separation Science Business Unit, based in the UK, will sit on the Humankind Ventures Board providing an opportunity to explore future collaboration with Forth.

The equity investment by Trajan of GBP 705,002 results in the issue of 235,298 new preferred ordinary shares giving Trajan a percentage of the share capital as follows: 9.55% non-diluted, 8.41% fully diluted, 9.85% voting.

Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated, "We have known the founders and majority shareholders at Forth for some time. We share common values around delivering good science that helps people achieve better health outcomes. We are both intensely focused on delivering impact and working together we believe we will do just that. Trajan is currently engaged in multiple investment and acquisition opportunities. The stake in Forth is one example that is relatively small in scale but of significant strategic importance."

Sarah Bolt, CEO and Co-Founder of Forth stated: "Our mission at Forth is simple - to give people a better understanding of their own body using a combination of science and technology. This investment will enable us to launch Female Hormone Mapping and also develop more unique and insightful products to help people engage proactively with their health. Trajan is a perfect partner as we share a focus on using science to advance preventative health."

Authorised for ASX release by the Board of Trajan Group Holdings Limited.

END



Contact:

Investors

Rebecca Wilson
WE Communications
investorrelations@trajanscimed.com

Media

Amy Miller
WE Communications
amymi@we-worldwide.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of 450 people, with five manufacturing sites across the US, Australia, and Malaysia, and operations in Australia, the US, Asia, and Europe.

About Forth

Launched in 2016, Forth is one of the UK's leading companies in personalised biomarker tracking. Starting with a small sample of blood, the company helps people to navigate their way to better health by providing clear scientific data about their body's biochemistry, together with expert advice to help them improve. Since starting to raise initial seed investment the company has gone from strength to strength and recently launched a ground-breaking product to help women gain better insight into their hormone fluctuations. Female Hormone Mapping is the first product in the world to use AI to help map how a woman's hormones fluctuate throughout their entire cycle, rather than a single day, which is current clinical practice.

For personal use only